My Website

Changing the world, one site at a time…


The Founders

Tsvetelina Lazarova, Ph.D. – Co-Founder
Dr. Lazarova has over 20 years of experience in organic chemistry, 15 of those in biotech in the Boston area. She was involved with 2 start-up companies. Dr. Lazarova received her B.A. degree in chemistry from Harvard University, M.A. in organic chemistry from MIT and PhD in organic Chemistry from University of California, Los Angeles. She studied with Profs. Stuart Schreiber, Stephen Buchwald and Michael E. Jung.

While at Enanta Pharmaceuticals, Dr. Lazarova initiated the chemistry portion of the immunology program and advanced two lead series to pre-clinical status as potential therapies for asthma and psoriasis. At Daiichi Asubio Research Laboratories, Dr. Lazarova led the nuclear hormone receptor project, which relied on structure guided drug design and rapid generation of focused libraries to develop novel cholesterol lowering agents.
Dr. Lazarova has also worked at ARIAD Pharmaceuticals (where she was the first chemist hired) where she worked with peptide mimetics involved in signal transduction pathways and on natural product analogs as potential protein transport inhibitors.

At Cubist Pharmaceuticals, Dr. Lazarova designed and synthesized second generation analogs of Daptomycin (CubicinTM), a novel lipopetide antibiotic used for the treatment of skin and soft tissue infections.
Steven Riesinger, Ph.D. – Co-Founder
Dr. Riesinger has over 20 years’ experience in organic chemistry, 15 of those in the biotech arena where he has been involved in the start up of three companies. Dr, Riesinger received his Ph.D. at Emory University in organic chemistry followed by postdoctoral fellowships at Uppsala University with Dr. Jan-E Bäckvall and at Montana State University in the laboratory of Dr. Tom Livinghouse.

During Dr. Riesinger’s tenure at Shionogi BioResearch he spearheaded the initial set up of the medicinal and combinatorial chemistry laboratories and was responsible for managing its lead anti-cancer program.
As a founding scientist at Enanta Pharmaceuticals, Dr. Riesinger played a lead role in setting up the company’s research laboratories, establishing the medicinal chemistry group, and directing its anti-viral programs, which ultimately produced protease inhibitors active in the single-digit nanomolar range